Other Events ·
Altimmune reports positive topline results from Phase 2 RECLAIM trial of pemvidutide for alcohol use disorder, meeting primary endpoint with statistically significant reduction in heavy drinking days
ALTAltimmune, Inc.
On July 28, 2026, Altimmune announced positive topline results from the Phase 2 RECLAIM trial evaluating pemvidutide 2.4 mg for moderate to severe alcohol use disorder. The trial met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (p=0.0014). Secondary endpoints included a two-level reduction in WHO Risk Drinking Levels (64.4% vs 34.8%, p=0.0049) and zero heavy drinking days (42.2% vs 17.4%, p=0.0066), both recognized by the FDA as registrational endpoints. The drug demonstrated a generally favorable safety profile, though nausea and vomiting were observed. Altimmune plans to request an End-of-Phase 2 meeting with the FDA and initiate a Phase 3 trial for MASH in Q3 2026. Altimmune is a late clinical-stage biopharmaceutical company developing therapies for serious liver diseases.